

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2021

**Editas Medicine, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37687**  
(Commission  
File Number)

**11 Hurley Street**  
**Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	EDIT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 4, 2021, Editas Medicine, Inc. (the "Company") appointed James C. Mullen as President and Chief Executive Officer of the Company effective as of February 15, 2021, succeeding Cynthia Collins as President and Chief Executive Officer of the Company. Ms. Collins also resigned as a member of the Company Board of Directors effective February 4, 2021.

Mr. Mullen, age 62, has been Chairman of the Board of Directors of the Company, since March 2018. He previously served as Chief Executive Officer and a director of Patheon N.V., a pharmaceutical contract development and manufacturing organization, from March 2011 until its acquisition by Thermo Fisher Scientific, Inc. ("Thermo Fisher"), a public biotechnology product development company, in August 2017. Prior to joining Patheon, from June 2000 to June 2010, Mr. Mullen served as the president and Chief Executive Officer of Biogen Inc. ("Biogen"), one of the world's largest biotechnology companies. Mr. Mullen held various operating positions at Biogen prior to becoming Chief Executive Officer, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Mr. Mullen has served on the board of directors of Thermo Fisher since November 2018. Mr. Mullen previously served on the board of directors of Insulet Corporation, a public medical device company, from September 2017 until January 2019 and PerkinElmer, Inc., a public technology and service provider for diagnostics, research, environmental and industrial and laboratory services markets, from 2003 to April 2015. He also previously served as Chairman of the Biotechnology Innovation Organization. Mr. Mullen received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.

In connection with her departure, Ms. Collins entered into a separation agreement with the Company that provides that Ms. Collins will receive an amount equivalent to 12 months of her current base salary, payable in installments in accordance with the Company's regular payroll practices, her 2020 bonus and benefits continuation for up to 12 months.

As of the date of this report, the Company and Mr. Mullen have not entered into an agreement with respect to Mr. Mullen's compensation and other terms of employment. When such agreement is entered into, the material terms of such arrangement will be disclosed in a subsequent filing.

On February 8, 2021, the Company issued a press release announcing Ms. Collins' departure and the appointment of Mr. Mullen as President and Chief Executive Officer. A copy of the press release is attached as Exhibit 99.1 to this report.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press release issued by the Company on February 8, 2021</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EDITAS MEDICINE, INC.**

Date: February 8, 2021

By: /s/ Michelle Robertson  
Michelle Robertson  
Chief Financial Officer

---



## Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

*Cindy Collins to Step Down Effective February 15, 2021*

**CAMBRIDGE, Mass., Feb. 8, 2021** – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will continue as Chairman of the Company’s Board of Directors.

“On behalf of the entire Board, I thank Cindy for her tremendous contributions and dedication to Editas Medicine,” said James C. Mullen, Chairman, Editas Medicine. “Under Cindy’s leadership, the Company initiated the EDIT-101 clinical trial – the first ever administration of an *in vivo* gene editing medicine in humans, filed an IND for EDIT-301 which the FDA cleared to initiate clinical trials, recovered the rights to the ocular programs and pipeline, and expanded the pre-clinical pipeline. Cindy has positioned Editas to achieve its long-term goals and deliver the potential of gene editing medicines to patients.”

Mr. Mullen continued, “It is an honor to be appointed to lead Editas into the next phase of growth. I look forward to joining such an innovative and committed team as we advance our strategy and work to develop and deliver transformative, durable gene edited medicines to people living with serious diseases.”

Ms. Collins said, “It has been a privilege to lead Editas Medicine and this extremely talented team. I am particularly proud of the progress to the clinic we have made with both *in vivo* and *ex vivo* gene edited medicines. I look forward to seeing Editas continue to develop the future of gene edited medicines and succeed on making these medicines for patients around the world.”

Mr. Mullen has served as chairman of the Board of Directors of Editas Medicine since March 2018. Mr. Mullen previously served as Chief Executive Officer and a director of Patheon N.V., a pharmaceutical contract development and manufacturing organization, until its acquisition by Thermo Fisher Scientific, Inc., in August 2017. Prior to joining Patheon, Mr. Mullen served as the president and Chief Executive Officer of Biogen, Inc., one of the world’s largest biotechnology companies. Mr. Mullen held various operating positions at Biogen prior to becoming Chief Executive Officer, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Mr. Mullen serves on the board of directors of Thermo Fisher Scientific. He also previously served as Chairman of the Biotechnology Innovation Organization. Mr. Mullen received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.

### About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit [www.editasmedicine.com](http://www.editasmedicine.com).

---

## Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

###

## Contacts:

### Media

Cristi Barnett  
(617) 401-0113  
[cristi.barnett@editasmed.com](mailto:cristi.barnett@editasmed.com)

### Investors

Editas Medicine Investor Relations  
(617) 401-9052  
[ir@editasmed.com](mailto:ir@editasmed.com)

---